GLP1R and Hypoglycemia: Tirzepatide is the first dual-target agonist that targets both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide (GIP) receptors, resulting in significant improvements in glucose control and weight without increasing the risk of hypoglycemia (Rosenstock et al., 2021).